Mepolizumab Efficacy in Patients with Severe Eosinophilic Asthma Receiving Different Controller Therapies

This post hoc analysis of the MENSA study demonstrates that mepolizumab reduced the annualized exacerbation rate relative to placebo in patients with severe eosinophilic asthma irrespective of the number or type of background controller therapies.

http://ift.tt/2tfdL3W